| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Breast Neoplasms | 39 | 2024 | 530 | 9.360 |
Why?
|
| Neoplastic Cells, Circulating | 28 | 2024 | 638 | 8.100 |
Why?
|
| Breast Neoplasms | 119 | 2024 | 16221 | 5.260 |
Why?
|
| Mastectomy | 27 | 2024 | 1557 | 2.340 |
Why?
|
| Sentinel Lymph Node Biopsy | 27 | 2022 | 1453 | 2.330 |
Why?
|
| Cyclooxygenase 2 | 13 | 2012 | 496 | 2.260 |
Why?
|
| Mastectomy, Segmental | 19 | 2024 | 1053 | 2.210 |
Why?
|
| Triple Negative Breast Neoplasms | 12 | 2024 | 1380 | 1.980 |
Why?
|
| Melanoma | 32 | 2022 | 5598 | 1.800 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 16 | 2019 | 695 | 1.760 |
Why?
|
| Lymphatic Metastasis | 32 | 2021 | 4965 | 1.670 |
Why?
|
| Lymph Nodes | 23 | 2022 | 3079 | 1.610 |
Why?
|
| Neoadjuvant Therapy | 33 | 2024 | 5224 | 1.550 |
Why?
|
| Circulating Tumor DNA | 3 | 2024 | 274 | 1.550 |
Why?
|
| Axilla | 20 | 2022 | 934 | 1.520 |
Why?
|
| Neoplasm Recurrence, Local | 32 | 2023 | 10370 | 1.480 |
Why?
|
| Carcinoma, Lobular | 9 | 2020 | 618 | 1.390 |
Why?
|
| Skin Neoplasms | 22 | 2022 | 4894 | 1.360 |
Why?
|
| Lymph Node Excision | 21 | 2022 | 2057 | 1.350 |
Why?
|
| Biomarkers, Tumor | 28 | 2024 | 10736 | 1.280 |
Why?
|
| Neoplasm Staging | 46 | 2022 | 14015 | 1.140 |
Why?
|
| Female | 167 | 2024 | 149106 | 1.130 |
Why?
|
| Practice Patterns, Physicians' | 9 | 2024 | 1317 | 1.060 |
Why?
|
| Prospective Studies | 37 | 2023 | 13385 | 0.990 |
Why?
|
| Receptor, ErbB-2 | 19 | 2023 | 2655 | 0.960 |
Why?
|
| Humans | 198 | 2024 | 271550 | 0.960 |
Why?
|
| Bone Marrow Neoplasms | 3 | 2011 | 128 | 0.920 |
Why?
|
| Carcinoma, Ductal, Breast | 15 | 2020 | 1237 | 0.910 |
Why?
|
| Prognosis | 46 | 2024 | 22524 | 0.840 |
Why?
|
| Breast | 8 | 2023 | 1378 | 0.830 |
Why?
|
| Thoracic Wall | 2 | 2023 | 188 | 0.780 |
Why?
|
| Neoplasm Micrometastasis | 2 | 2012 | 50 | 0.780 |
Why?
|
| Neoplasm Metastasis | 16 | 2020 | 5315 | 0.710 |
Why?
|
| Margins of Excision | 3 | 2019 | 315 | 0.700 |
Why?
|
| Middle Aged | 97 | 2024 | 90422 | 0.700 |
Why?
|
| Neoplasm Invasiveness | 11 | 2018 | 4061 | 0.690 |
Why?
|
| Decision Making | 5 | 2017 | 1250 | 0.690 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2019 | 11 | 0.670 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 2 | 2016 | 27 | 0.670 |
Why?
|
| Surgeons | 3 | 2024 | 487 | 0.650 |
Why?
|
| Nipples | 1 | 2019 | 124 | 0.640 |
Why?
|
| Sentinel Lymph Node | 2 | 2021 | 229 | 0.630 |
Why?
|
| Aged | 77 | 2024 | 73451 | 0.620 |
Why?
|
| Receptors, CXCR4 | 3 | 2010 | 279 | 0.590 |
Why?
|
| Adult | 78 | 2024 | 82003 | 0.580 |
Why?
|
| General Surgery | 5 | 2005 | 331 | 0.580 |
Why?
|
| Pain, Postoperative | 3 | 2021 | 659 | 0.570 |
Why?
|
| Lymphedema | 6 | 2022 | 239 | 0.560 |
Why?
|
| Nerve Block | 2 | 2009 | 185 | 0.560 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2024 | 16646 | 0.560 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 5 | 2010 | 198 | 0.560 |
Why?
|
| Patient Selection | 5 | 2019 | 2033 | 0.540 |
Why?
|
| Receptors, Estrogen | 10 | 2020 | 2166 | 0.530 |
Why?
|
| Mammaplasty | 5 | 2019 | 715 | 0.530 |
Why?
|
| Ceramides | 4 | 1999 | 91 | 0.530 |
Why?
|
| Bone Marrow | 4 | 2020 | 2439 | 0.520 |
Why?
|
| Body Mass Index | 7 | 2017 | 2247 | 0.490 |
Why?
|
| Bone Neoplasms | 6 | 2019 | 2670 | 0.490 |
Why?
|
| Guideline Adherence | 2 | 2018 | 643 | 0.480 |
Why?
|
| Genomic Instability | 2 | 2008 | 522 | 0.470 |
Why?
|
| Drug Resistance, Multiple | 4 | 1999 | 221 | 0.470 |
Why?
|
| Neoplastic Stem Cells | 7 | 2013 | 1458 | 0.460 |
Why?
|
| Neoplasm, Residual | 5 | 2019 | 1740 | 0.460 |
Why?
|
| Receptors, Progesterone | 7 | 2020 | 1609 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 5 | 2022 | 2422 | 0.460 |
Why?
|
| Antineoplastic Agents | 18 | 2018 | 14631 | 0.450 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2005 | 231 | 0.450 |
Why?
|
| Peptides | 2 | 2010 | 1505 | 0.440 |
Why?
|
| Follow-Up Studies | 29 | 2024 | 15247 | 0.430 |
Why?
|
| Societies, Medical | 3 | 2024 | 1347 | 0.430 |
Why?
|
| Disease-Free Survival | 20 | 2024 | 10258 | 0.430 |
Why?
|
| Adaptation, Physiological | 1 | 2014 | 348 | 0.420 |
Why?
|
| Rosaniline Dyes | 4 | 2017 | 109 | 0.410 |
Why?
|
| Aged, 80 and over | 40 | 2020 | 31066 | 0.410 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2014 | 5407 | 0.410 |
Why?
|
| Adaptation, Biological | 1 | 2012 | 48 | 0.400 |
Why?
|
| Disease Progression | 11 | 2020 | 6857 | 0.400 |
Why?
|
| Transcriptome | 4 | 2022 | 1953 | 0.380 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 1005 | 0.380 |
Why?
|
| Mice, Nude | 8 | 2016 | 4348 | 0.370 |
Why?
|
| Mastectomy, Simple | 3 | 2017 | 59 | 0.370 |
Why?
|
| Consensus | 3 | 2024 | 1115 | 0.370 |
Why?
|
| Survival Rate | 15 | 2022 | 12528 | 0.360 |
Why?
|
| Obesity | 5 | 2017 | 2915 | 0.350 |
Why?
|
| Gene Amplification | 1 | 2013 | 767 | 0.350 |
Why?
|
| Genetic Testing | 1 | 2017 | 1699 | 0.320 |
Why?
|
| Precision Medicine | 4 | 2022 | 1206 | 0.320 |
Why?
|
| Tumor Cells, Cultured | 9 | 2014 | 5762 | 0.310 |
Why?
|
| Suture Techniques | 1 | 2010 | 292 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2020 | 9053 | 0.310 |
Why?
|
| Cell Line, Tumor | 13 | 2016 | 14818 | 0.300 |
Why?
|
| Career Choice | 3 | 2005 | 209 | 0.290 |
Why?
|
| Breast Diseases | 1 | 2009 | 206 | 0.290 |
Why?
|
| Liquid Biopsy | 3 | 2023 | 162 | 0.290 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2010 | 291 | 0.280 |
Why?
|
| Pyrazoles | 3 | 2010 | 1540 | 0.270 |
Why?
|
| Sulfonamides | 4 | 2010 | 1932 | 0.270 |
Why?
|
| Interleukin-11 | 1 | 2006 | 38 | 0.260 |
Why?
|
| Genes, erbB-2 | 4 | 2012 | 228 | 0.260 |
Why?
|
| Treatment Outcome | 24 | 2024 | 33870 | 0.260 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2006 | 46 | 0.260 |
Why?
|
| Proportional Hazards Models | 9 | 2022 | 5099 | 0.250 |
Why?
|
| Fee Schedules | 1 | 2004 | 3 | 0.250 |
Why?
|
| Interleukin-12 Subunit p40 | 2 | 2015 | 30 | 0.250 |
Why?
|
| Adenocarcinoma | 5 | 2019 | 7937 | 0.250 |
Why?
|
| Dermatofibrosarcoma | 1 | 2005 | 73 | 0.240 |
Why?
|
| Transfection | 5 | 2008 | 3130 | 0.240 |
Why?
|
| Doxorubicin | 5 | 2012 | 3144 | 0.240 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2019 | 837 | 0.240 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2004 | 67 | 0.230 |
Why?
|
| Tamoxifen | 5 | 2019 | 875 | 0.230 |
Why?
|
| Epithelial Cells | 2 | 2011 | 1887 | 0.230 |
Why?
|
| Interleukin-8 | 1 | 2006 | 531 | 0.230 |
Why?
|
| Mice | 13 | 2022 | 35697 | 0.220 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2007 | 554 | 0.220 |
Why?
|
| Lidocaine | 1 | 2003 | 79 | 0.220 |
Why?
|
| Postoperative Complications | 5 | 2013 | 5697 | 0.210 |
Why?
|
| Surgical Oncology | 2 | 2024 | 208 | 0.210 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2005 | 235 | 0.210 |
Why?
|
| Blotting, Western | 4 | 2014 | 3610 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 12 | 2020 | 3988 | 0.210 |
Why?
|
| Retrospective Studies | 23 | 2024 | 39818 | 0.210 |
Why?
|
| Neurilemmoma | 1 | 2003 | 134 | 0.200 |
Why?
|
| Survival Analysis | 12 | 2022 | 9307 | 0.200 |
Why?
|
| Skin Transplantation | 1 | 2003 | 184 | 0.200 |
Why?
|
| Medicare | 2 | 2024 | 932 | 0.200 |
Why?
|
| Epinephrine | 1 | 2003 | 249 | 0.200 |
Why?
|
| Carbon | 2 | 2001 | 164 | 0.200 |
Why?
|
| Parathyroid Neoplasms | 1 | 2023 | 188 | 0.200 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2022 | 40 | 0.200 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 560 | 0.200 |
Why?
|
| Feasibility Studies | 5 | 2023 | 2364 | 0.200 |
Why?
|
| Pelvic Neoplasms | 1 | 2003 | 203 | 0.190 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 102 | 0.190 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 3850 | 0.190 |
Why?
|
| Interdisciplinary Studies | 1 | 2021 | 6 | 0.190 |
Why?
|
| Standard of Care | 2 | 2020 | 275 | 0.190 |
Why?
|
| Students, Medical | 2 | 2005 | 421 | 0.190 |
Why?
|
| Cell Survival | 4 | 2016 | 3068 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 232 | 0.190 |
Why?
|
| Celecoxib | 3 | 2010 | 198 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 135 | 0.190 |
Why?
|
| False Negative Reactions | 2 | 2017 | 295 | 0.190 |
Why?
|
| Risk Assessment | 9 | 2020 | 6845 | 0.190 |
Why?
|
| Young Adult | 21 | 2024 | 22190 | 0.190 |
Why?
|
| Animals | 15 | 2022 | 62359 | 0.180 |
Why?
|
| Reoperation | 2 | 2024 | 1393 | 0.180 |
Why?
|
| Male | 34 | 2023 | 128724 | 0.180 |
Why?
|
| Inflammation | 4 | 2019 | 2531 | 0.180 |
Why?
|
| Cell Separation | 2 | 2016 | 614 | 0.180 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2021 | 131 | 0.180 |
Why?
|
| Self Report | 1 | 2024 | 792 | 0.180 |
Why?
|
| Isoenzymes | 1 | 2002 | 655 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 383 | 0.170 |
Why?
|
| Dissection | 1 | 2020 | 133 | 0.170 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 1012 | 0.170 |
Why?
|
| Surveys and Questionnaires | 7 | 2024 | 5936 | 0.170 |
Why?
|
| Combined Modality Therapy | 7 | 2023 | 9049 | 0.170 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2020 | 36 | 0.170 |
Why?
|
| Alpha Particles | 1 | 2019 | 26 | 0.170 |
Why?
|
| Needs Assessment | 1 | 2001 | 237 | 0.170 |
Why?
|
| SEER Program | 3 | 2019 | 1051 | 0.170 |
Why?
|
| United States | 14 | 2024 | 16006 | 0.170 |
Why?
|
| Odds Ratio | 3 | 2015 | 2325 | 0.160 |
Why?
|
| Databases, Factual | 4 | 2019 | 2282 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 2459 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2016 | 3908 | 0.160 |
Why?
|
| Pilot Projects | 4 | 2021 | 2857 | 0.160 |
Why?
|
| Image-Guided Biopsy | 2 | 2019 | 337 | 0.160 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 745 | 0.160 |
Why?
|
| Gene Expression Profiling | 5 | 2022 | 5163 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 2 | 2022 | 2390 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2021 | 1824 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2024 | 699 | 0.160 |
Why?
|
| Radium | 1 | 2019 | 97 | 0.160 |
Why?
|
| Preoperative Period | 2 | 2017 | 348 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Glucosylceramides | 1 | 1998 | 5 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 4493 | 0.150 |
Why?
|
| Trastuzumab | 6 | 2010 | 742 | 0.150 |
Why?
|
| Scalp | 1 | 2019 | 155 | 0.150 |
Why?
|
| Bone Marrow Examination | 2 | 2008 | 151 | 0.150 |
Why?
|
| Neoplasms | 6 | 2021 | 15903 | 0.150 |
Why?
|
| Conservative Treatment | 1 | 2018 | 66 | 0.150 |
Why?
|
| Genomics | 3 | 2017 | 2825 | 0.150 |
Why?
|
| Cell Movement | 1 | 2005 | 2484 | 0.150 |
Why?
|
| Technetium | 1 | 2017 | 80 | 0.150 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 280 | 0.140 |
Why?
|
| Dinoprostone | 3 | 2010 | 221 | 0.140 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 410 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2021 | 1054 | 0.140 |
Why?
|
| MicroRNAs | 3 | 2023 | 2902 | 0.140 |
Why?
|
| Risk Factors | 11 | 2020 | 17982 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2018 | 424 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 3 | 2018 | 1387 | 0.140 |
Why?
|
| Incidence | 10 | 2020 | 5848 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 858 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 6205 | 0.140 |
Why?
|
| Oximes | 1 | 2018 | 191 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 482 | 0.130 |
Why?
|
| Repressor Proteins | 2 | 2016 | 1715 | 0.130 |
Why?
|
| Propensity Score | 1 | 2019 | 773 | 0.130 |
Why?
|
| Immunohistochemistry | 7 | 2011 | 7790 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 6264 | 0.130 |
Why?
|
| Pyrimidinones | 1 | 2018 | 318 | 0.130 |
Why?
|
| Aldehyde Dehydrogenase | 2 | 2013 | 105 | 0.130 |
Why?
|
| Neoplasm Grading | 3 | 2016 | 1823 | 0.130 |
Why?
|
| Seroma | 3 | 2016 | 78 | 0.130 |
Why?
|
| Pyridones | 1 | 2018 | 361 | 0.120 |
Why?
|
| Ultrasonography, Mammary | 3 | 2010 | 387 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 700 | 0.120 |
Why?
|
| Homeodomain Proteins | 3 | 2016 | 1125 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2016 | 406 | 0.120 |
Why?
|
| Pain Measurement | 2 | 2009 | 1016 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 1329 | 0.120 |
Why?
|
| Mastectomy, Modified Radical | 2 | 2006 | 75 | 0.120 |
Why?
|
| Transcription Factors | 3 | 2016 | 5451 | 0.120 |
Why?
|
| Immunoassay | 2 | 2006 | 214 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 549 | 0.120 |
Why?
|
| Radiotherapy | 3 | 2018 | 1861 | 0.120 |
Why?
|
| Pancreatectomy | 1 | 2019 | 696 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2018 | 1839 | 0.120 |
Why?
|
| Breast Implants | 1 | 2019 | 376 | 0.120 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 678 | 0.110 |
Why?
|
| Phenotype | 5 | 2020 | 6493 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 262 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1121 | 0.110 |
Why?
|
| Ipilimumab | 1 | 2018 | 759 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 1427 | 0.110 |
Why?
|
| Ultrasonography | 2 | 2017 | 1935 | 0.110 |
Why?
|
| Immunophenotyping | 2 | 2016 | 1731 | 0.110 |
Why?
|
| Bone Marrow Cells | 3 | 2013 | 970 | 0.110 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1968 | 0.110 |
Why?
|
| Multivariate Analysis | 6 | 2020 | 4337 | 0.110 |
Why?
|
| Octamer Transcription Factor-3 | 2 | 2010 | 106 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 2 | 2023 | 693 | 0.110 |
Why?
|
| Chemoradiotherapy | 2 | 2019 | 2028 | 0.100 |
Why?
|
| Immunotherapy | 3 | 2022 | 3547 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2010 | 1545 | 0.100 |
Why?
|
| Radionuclide Imaging | 2 | 2006 | 657 | 0.100 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 138 | 0.100 |
Why?
|
| Cohort Studies | 7 | 2024 | 9477 | 0.100 |
Why?
|
| Gene Expression | 2 | 2012 | 3658 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 692 | 0.100 |
Why?
|
| Length of Stay | 2 | 2009 | 2010 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 553 | 0.100 |
Why?
|
| Mammography | 4 | 2018 | 1054 | 0.100 |
Why?
|
| Imidazoles | 1 | 2018 | 1058 | 0.100 |
Why?
|
| Exosomes | 1 | 2014 | 255 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 1466 | 0.100 |
Why?
|
| Vimentin | 1 | 2012 | 260 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 5030 | 0.090 |
Why?
|
| Polypropylenes | 1 | 2010 | 25 | 0.090 |
Why?
|
| Medicine | 1 | 2012 | 140 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 1206 | 0.090 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2010 | 14 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2022 | 2357 | 0.090 |
Why?
|
| Paresthesia | 2 | 2007 | 33 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2013 | 2314 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 787 | 0.090 |
Why?
|
| Gangliosides | 1 | 2011 | 97 | 0.090 |
Why?
|
| Esthetics | 1 | 2010 | 116 | 0.090 |
Why?
|
| Keratins | 2 | 2009 | 349 | 0.090 |
Why?
|
| Glutamine | 1 | 2012 | 326 | 0.090 |
Why?
|
| Inguinal Canal | 1 | 2010 | 64 | 0.090 |
Why?
|
| Positron-Emission Tomography | 3 | 2018 | 2199 | 0.090 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2010 | 106 | 0.090 |
Why?
|
| Sutures | 1 | 2010 | 93 | 0.090 |
Why?
|
| Nomograms | 1 | 2012 | 313 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 3496 | 0.080 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 125 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2011 | 7259 | 0.080 |
Why?
|
| Hormone Antagonists | 2 | 1999 | 116 | 0.080 |
Why?
|
| Mifepristone | 2 | 1999 | 180 | 0.080 |
Why?
|
| Time Factors | 6 | 2015 | 13077 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 7916 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 5185 | 0.080 |
Why?
|
| Cell Culture Techniques | 2 | 2010 | 583 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2012 | 889 | 0.080 |
Why?
|
| Cadherins | 1 | 2012 | 671 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 347 | 0.080 |
Why?
|
| Cytological Techniques | 1 | 2009 | 75 | 0.080 |
Why?
|
| Anesthesia, Conduction | 1 | 2009 | 44 | 0.080 |
Why?
|
| Surgical Wound Infection | 2 | 2010 | 481 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 5771 | 0.080 |
Why?
|
| Estrogen Antagonists | 2 | 1999 | 188 | 0.080 |
Why?
|
| Frozen Sections | 1 | 2009 | 117 | 0.080 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 1589 | 0.080 |
Why?
|
| Valproic Acid | 1 | 2010 | 274 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 3621 | 0.080 |
Why?
|
| Carcinogenesis | 1 | 2014 | 1035 | 0.080 |
Why?
|
| Apoptosis | 2 | 1999 | 7783 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1204 | 0.080 |
Why?
|
| Colony-Forming Units Assay | 1 | 2008 | 253 | 0.080 |
Why?
|
| Adolescent | 9 | 2024 | 32726 | 0.080 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 552 | 0.070 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2010 | 366 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2010 | 4895 | 0.070 |
Why?
|
| Portal Vein | 2 | 2021 | 363 | 0.070 |
Why?
|
| Vomiting | 1 | 2009 | 361 | 0.070 |
Why?
|
| Patient Care Planning | 2 | 2011 | 304 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 1018 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2419 | 0.070 |
Why?
|
| Exudates and Transudates | 1 | 2007 | 57 | 0.070 |
Why?
|
| Nausea | 1 | 2009 | 540 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 842 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 3449 | 0.070 |
Why?
|
| Cyclosporine | 2 | 1999 | 295 | 0.070 |
Why?
|
| Postoperative Care | 2 | 2012 | 730 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2014 | 6436 | 0.070 |
Why?
|
| Anoikis | 1 | 2007 | 63 | 0.070 |
Why?
|
| Brachial Plexus | 1 | 2007 | 47 | 0.070 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 495 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 636 | 0.070 |
Why?
|
| Coloring Agents | 2 | 2010 | 234 | 0.070 |
Why?
|
| DNA, Complementary | 1 | 2008 | 944 | 0.070 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2007 | 169 | 0.070 |
Why?
|
| Taxoids | 2 | 2015 | 1007 | 0.070 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 574 | 0.070 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2006 | 113 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 316 | 0.070 |
Why?
|
| Proteins | 1 | 2014 | 2050 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2007 | 173 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2011 | 1429 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 689 | 0.070 |
Why?
|
| Income | 2 | 2005 | 230 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 440 | 0.060 |
Why?
|
| Case-Control Studies | 4 | 2016 | 6234 | 0.060 |
Why?
|
| Mammary Glands, Human | 1 | 2006 | 184 | 0.060 |
Why?
|
| Membrane Proteins | 3 | 2005 | 2949 | 0.060 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 1338 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2018 | 751 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 177 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 1078 | 0.060 |
Why?
|
| Quinazolines | 1 | 2009 | 956 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 742 | 0.060 |
Why?
|
| Pregnancy | 3 | 2022 | 8110 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 696 | 0.060 |
Why?
|
| Age Factors | 5 | 2016 | 5502 | 0.060 |
Why?
|
| Signal Transduction | 5 | 2019 | 12134 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2010 | 2438 | 0.060 |
Why?
|
| Pharmaceutical Solutions | 1 | 2003 | 22 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2008 | 7404 | 0.060 |
Why?
|
| Minority Groups | 1 | 2006 | 327 | 0.050 |
Why?
|
| Cell Line | 2 | 2010 | 5373 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 5252 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 4651 | 0.050 |
Why?
|
| Life Style | 2 | 2005 | 621 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2019 | 880 | 0.050 |
Why?
|
| Interleukins | 1 | 2005 | 341 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 4139 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2008 | 531 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 343 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2023 | 199 | 0.050 |
Why?
|
| Surgical Instruments | 1 | 2003 | 138 | 0.050 |
Why?
|
| Health Plan Implementation | 1 | 2003 | 90 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2007 | 914 | 0.050 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2005 | 201 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2015 | 2274 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2010 | 2104 | 0.050 |
Why?
|
| Texas | 3 | 2018 | 6444 | 0.050 |
Why?
|
| CD24 Antigen | 2 | 2013 | 88 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 810 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 379 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1401 | 0.050 |
Why?
|
| Biopsy | 2 | 2010 | 3537 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 2452 | 0.050 |
Why?
|
| Skin Pigmentation | 1 | 2001 | 50 | 0.050 |
Why?
|
| Kidney | 1 | 2010 | 2251 | 0.050 |
Why?
|
| Private Practice | 1 | 2001 | 34 | 0.050 |
Why?
|
| Hyaluronan Receptors | 2 | 2013 | 249 | 0.050 |
Why?
|
| Sunlight | 1 | 2001 | 80 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2007 | 2142 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 526 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 1065 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2006 | 1556 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2010 | 3396 | 0.040 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2020 | 40 | 0.040 |
Why?
|
| Estradiol | 1 | 2023 | 835 | 0.040 |
Why?
|
| Cyclosporins | 1 | 1999 | 115 | 0.040 |
Why?
|
| International Cooperation | 2 | 2014 | 327 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 263 | 0.040 |
Why?
|
| Denosumab | 1 | 2019 | 72 | 0.040 |
Why?
|
| Progestins | 1 | 1999 | 92 | 0.040 |
Why?
|
| Lung Neoplasms | 3 | 2011 | 12032 | 0.040 |
Why?
|
| Estrogens | 1 | 2023 | 816 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 323 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2001 | 237 | 0.040 |
Why?
|
| Radioisotopes | 1 | 2019 | 177 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 1999 | 163 | 0.040 |
Why?
|
| DNA Damage | 1 | 2007 | 1987 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2019 | 592 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 4976 | 0.040 |
Why?
|
| Foot Diseases | 1 | 1999 | 49 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 7792 | 0.040 |
Why?
|
| Biomarkers | 2 | 2021 | 5086 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 588 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 272 | 0.040 |
Why?
|
| Leukopenia | 1 | 2018 | 153 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 316 | 0.040 |
Why?
|
| Alopecia | 1 | 2018 | 124 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 380 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1999 | 563 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 274 | 0.040 |
Why?
|
| Algorithms | 2 | 2006 | 3925 | 0.040 |
Why?
|
| Drug Interactions | 1 | 1999 | 582 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 864 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2003 | 740 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 723 | 0.040 |
Why?
|
| Glycosphingolipids | 1 | 1997 | 21 | 0.040 |
Why?
|
| Verapamil | 1 | 1997 | 85 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 3455 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 102 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2019 | 608 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1360 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 2482 | 0.030 |
Why?
|
| ROC Curve | 2 | 2012 | 1250 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 552 | 0.030 |
Why?
|
| Quality of Life | 2 | 2023 | 4764 | 0.030 |
Why?
|
| Carboxypeptidases | 1 | 2014 | 25 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 530 | 0.030 |
Why?
|
| Argonaute Proteins | 1 | 2014 | 42 | 0.030 |
Why?
|
| Bridged-Ring Compounds | 1 | 2015 | 180 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 2248 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2016 | 244 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2014 | 157 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 701 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1248 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 629 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 912 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2001 | 1442 | 0.030 |
Why?
|
| Ribonuclease III | 1 | 2014 | 188 | 0.030 |
Why?
|
| Anthracyclines | 1 | 2015 | 339 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2014 | 276 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 300 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 549 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 908 | 0.030 |
Why?
|
| Recurrence | 2 | 2012 | 4882 | 0.030 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 263 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 1440 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 1095 | 0.030 |
Why?
|
| Residual Volume | 1 | 2012 | 11 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3022 | 0.020 |
Why?
|
| Fatigue | 1 | 2018 | 1279 | 0.020 |
Why?
|
| ErbB Receptors | 2 | 2011 | 2380 | 0.020 |
Why?
|
| Lymphatic Irradiation | 1 | 2012 | 139 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2003 | 1441 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 1578 | 0.020 |
Why?
|
| Polycomb-Group Proteins | 1 | 2011 | 42 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 4961 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1092 | 0.020 |
Why?
|
| Patient Care | 1 | 2012 | 151 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1697 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 5082 | 0.020 |
Why?
|
| Snail Family Transcription Factors | 1 | 2011 | 121 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 2357 | 0.020 |
Why?
|
| Isoindoles | 1 | 2010 | 9 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2011 | 192 | 0.020 |
Why?
|
| Prostaglandins E | 1 | 2010 | 22 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2010 | 88 | 0.020 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 1 | 2010 | 11 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2010 | 81 | 0.020 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2010 | 23 | 0.020 |
Why?
|
| Twist-Related Protein 1 | 1 | 2011 | 132 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2011 | 167 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2011 | 160 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 2223 | 0.020 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2010 | 50 | 0.020 |
Why?
|
| Rats | 1 | 1999 | 6595 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 397 | 0.020 |
Why?
|
| Marital Status | 1 | 2010 | 93 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 602 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 729 | 0.020 |
Why?
|
| Nanog Homeobox Protein | 1 | 2010 | 64 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2010 | 231 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2011 | 263 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2078 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 2010 | 129 | 0.020 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2010 | 120 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2010 | 259 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2010 | 217 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 550 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 649 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2009 | 256 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 1022 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2010 | 4157 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2008 | 24 | 0.020 |
Why?
|
| Groin | 1 | 2008 | 78 | 0.020 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 47 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2007 | 2659 | 0.020 |
Why?
|
| Suction | 1 | 2008 | 112 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2009 | 398 | 0.020 |
Why?
|
| Aromatase Inhibitors | 1 | 2010 | 310 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 2058 | 0.020 |
Why?
|
| Mesoderm | 1 | 2009 | 396 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2009 | 463 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 2048 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2010 | 359 | 0.020 |
Why?
|
| Epithelium | 1 | 2009 | 797 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 3942 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 2008 | 196 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 4266 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 1943 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 764 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 2034 | 0.020 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2006 | 110 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 3653 | 0.020 |
Why?
|
| American Cancer Society | 1 | 2006 | 35 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2012 | 1261 | 0.020 |
Why?
|
| Role | 1 | 2005 | 47 | 0.020 |
Why?
|
| Hematoma | 1 | 2006 | 159 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 2199 | 0.020 |
Why?
|
| Anaphylaxis | 1 | 2006 | 123 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2011 | 3073 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 3675 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 3531 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2012 | 5740 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 968 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 1568 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 2203 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 1586 | 0.010 |
Why?
|
| Attitude | 1 | 2003 | 163 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 2324 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1416 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 1128 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 2685 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2005 | 1495 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 2003 | 356 | 0.010 |
Why?
|
| Child | 1 | 2001 | 30545 | 0.010 |
Why?
|
| Research Design | 1 | 2007 | 1574 | 0.010 |
Why?
|
| Education, Medical | 1 | 2003 | 344 | 0.010 |
Why?
|
| Leg | 1 | 1999 | 216 | 0.010 |
Why?
|
| Meperidine | 1 | 1997 | 11 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 15918 | 0.010 |
Why?
|
| Glycosylation | 1 | 1997 | 230 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 4505 | 0.010 |
Why?
|